CANCER BUZZ speaks with Aaron Cumpston, PharmD, and Christine Barrett, PharmD, BCOP, who discuss the challenges of care coordination and therapy and share operational best practices for the delivery of bispecific antibodies in the community setting.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Advancements in clinical data and research have shown the immunotherapeutic potential of bispecific antibodies as treatment for hematologic cancers and solid tumors. In this episode, CANCER BUZZ speaks with Aaron Cumpston, PharmD, pharmacy clinical specialist in hematologic malignancies and bone marrow transplant and Christine Barrett, PharmD, BCOP, medical oncology clinical pharmacy specialist at WVU Cancer Institute who discusses the challenges of care coordination and therapy and shares operational best practices for the delivery of bispecific antibodies in the community setting.
“I think we’re finding these drugs [bispecific T-cell engagers (BiTE) therapies] to be highly effective and having high response rates and also very durable response rates in very refractory patients.”—Aaron Cumpston, PharmD, BCOP
“I know that in community practice it can be really difficult, but there is a network of institutions out there that have taken on administering these BiTE therapies and have a lot of experience that can be very helpful for those in community practice.” —Christine Barrett, PharmD, BCOP
Guests:
Aaron Cumpston, PharmD, BCOP
Pharmacy Clinical Specialist – Hematologic Malignancy, Transplant, and Cellular Therapy
WVU Medicine
WVU Cancer Institute - Mary Babb Randolph Cancer Center
Morgantown, WV
Christine Barrett, PharmD, BCOP
Medical Oncology Clinical Pharmacy Specialist
WVU Medicine
WVU Cancer Institute - Mary Babb Randolph Cancer Center
Morgantown, WV
This episode was developed in connection with the ACCC education program Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumor and is supported by Amgen.
Resources:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
April 7, 2025
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
![Exploring Bispecific Antibodies in Community Oncology: Overcoming Challenges and Harnessing Opportunities – [Video Podcast] Ep 52](https://cdn.sanity.io/images/0vv8moc6/accc-cancer/83fbc5d451f70ee2266dee4ec0c4fabb62db403a-60x60.png)
